F. Andrè, Villejuif (France)

F. Boccardo, Genoa (Italy)

E. Bria, Rome (Italy)

H.J. Burstein, Boston - MA (USA)

P. Carlini, Rome (Italy)

M. Cobleigh, Chicago - IL (USA)

F. Cognetti, Rome (Italy)

P.F. Conte, Modena (Italy)

H. Cortes Funes, Madrid (Spain)

M. Cristofanilli, Philadelphia - PA (USA)

M. De Laurentiis, Naples (Italy)

S. De Placido, Naples (Italy)

A. Di Leo, Prato (Italy)

A. Fabi, Rome (Italy)

M. Fornier, New York - NY (USA)

K. Gelmon, Vancouver - BC (Canada)

L. Gianni, Milan (Italy)

C.A. Hudis, New York - NY (USA)

S. Iacobelli, Chieti (Italy)

N. Ibrahim, Houston - TX (USA)

W. Jonat, Kiel (Germany)

H. Mouridsen, København (Denmark)

C. Nisticò, Rome (Italy)

P. Papaldo, Rome (Italy)

E. Perez, Jacksonville - FL (USA)

P. Pronzato, Genoa (Italy)

G. Tortora, Naples (Italy)

Major Sponsors



Roc

We Innovate Healthcare

Sponsors

















Supporters





We also thank AMGEN DOMPÉ, MSD ITALIA, PIERRE FABRE for their support to the Congress.



Organizing Secreteriat

AIM Group International

Rome office: Via Flaminia, 1068 - 00189 Rome

Ph. 06 33053.1 - Fax 06 33053249

breastcancer2011@aimgroup.eu

www.aimgroupinternational.com/2011/breastcancer



2nd International Meeting on New Drugs in Breast Cancer

Rome, October 13 - 14, 2011 Regina Elena National Cancer Institute Bastianelli Congress Center



Welcome Letter

Dear Colleagues and Friends,
It is with great pleasure that, following the great success reached during
the 1st International Meeting on New Drugs in Breast Cancer, I am
pleased to announce that the 2nd International Meeting on New Drugs
in Breast Cancer will be held in Rome at the Regina Elena National
Cancer Institute, on October 13-14, 2011.

New exciting developments have occurred during the last few years that opened new perspectives for a better treatment of our patients.

The Scientific Board and myself will focus our attention on the important clinical updates on new drugs in Breast Cancer.

The Scientific Programme of the Meeting will include topics on Target Therapy, on Chemotherapy and on Hormonal therapy.

The programme was designed in the pursuit of excellence and all lectures will be presented by an international distinguished outstanding faculty which will report all their experiences and developments.

The meeting will take place in the beautiful city of Rome, the weather during the month of October is usually warm and extremely pleasant and I am sure there will be plenty opportunities for a unique and enjoyable stay in our city



	8.00	Registration				
	8.45	Welcome Lecture F. Cognetti				
	1 ST SE	1 ST SESSION: TARGET THERAPY				
	9.00	Presenting: F. Cognetti LECTURE "Integration of molecular profiling with clinical practice" E. Perez				
	9.30	LECTURE "Circulating Tumor Cells: Where are we?" M. Cristofanilli				
1st Panel Chairmen: F. Cognetti, G. Tortora						
HER2 FAMILY INHIBITORS		HER2 FAMILY INHIBITORS				
		Dual EGFR and HER2 inhibitors				
	10.00	Trastuzumab: the start of a new era? $F. An\partial r\hat{e}$				
	10.20	T-DM1: the update H.J. Burstein				
	10.40	Lapatinib: new prospectives in early breast cancer <i>TBD</i>				
	11.00	Neratinib in metastatic breast cancer: the new investigations <i>R. Colomer</i>				
	11.20	Pertuzumab: in association with chemotherapy or with target therapy <i>L. Gianni</i>				
	11.40	Cetuximab in breast cancer A. Di Leo				
	Coffee	Coffee break				

	2nd Panel Chairmen: S. De Placido, A. Di Leo					
	Angiogenesis Family inhibitors					
12.20	Bevacizumab: the role in adjuvant setting M. Cobleigh					
12.40	Sorafenib: what news? H. Cortes Funes					
13.00	Ramucirumab: activity and developments in breast cancer <i>TBD</i>					
Buffet	Buffet Lunch					
	PI3K/AKT/mammalian target of rapamycin patway inhibitors					
14.30	Everolimus: alone and in association in metastatic disease <i>W. Jonat</i>					
14.50	Temsirolimus: activity in hormonal receptor positive postmenopausal patients <i>TBD</i>					
	Protein Kinase C(beta)-Selective Inhibitor					
15.10	Enzastaurin: combinations with chemotherapy and antiangiogenetic agents <i>K. Gelmon</i>					
	PARP inhibition: DNA Repair as the target					
15.30	Second thoughts have been given about its efficacy <i>G. Tortora</i>					
15.50	Round Table Expert's opinion Chairperson: G. Tortora Discussants: E. Bria, S. De Placido, A. Fabi, S. Iacobelli, C. Nisticò					

October

Thursday,

8.30 Registration

2ND SESSION: CYTOTOXIC DRUGS

Presenting: F. Cognetti 9.00 LECTURE "Adjuvant treatment: chemotherapy or not chemotherapy in node positive hormonal responsive breast cancer patients: the current dualism" E. Perez

09.30 LECTURE "Is there a best therapy for triple negative metastatic breast cancer?" С.А. Нидіз

Chairmen: P.F. Conte

10.00 The new taxane formulation Nab - Paclitaxel: a new generation of taxane N. Ibrahim

10.20 Non-taxane microtubuledynamic inhibitor Eribulin mesylate: update

10.40 New Bisphosfonate Denosumab: the last or the new treatment in controlling bone metastases? M. Fornier

Coffee break

3RD SESSION: HORMONAL THERAPY

Presenting: .	P. Pronzato		
LECTURE '	"What's new in	hormone recei	otor-positive

11.20 breast cancer?" H. Mouridsen

Chairmen: TBD

11.50 Hormonal manipulation in pre menopausal women F. Boccardo

12.10 How to overcome hormonal resistance: new drugs, biologics? P. Pronzato

12.30 **Round Table** Expert's opinion Chairperson: P. Pronzato Discussants: F. Boccardo, P. Carlini, P.F. Conte, M. De Laurentiis, F.P. Papaldo

Buffet Lunch

October

Scientific Committee

P. Conte (Modena, I) S. De Placido (Naples, I)

A. Di Leo (Prato, I)

L. Gianni (Milan, I)

G. Tortora (Naples, I)

M. Venturini (Negrar-VR, I)

Local Scientific Secretariat Emilio Bria Paolo Carlini Alessandra Fabi Cecilia Nisticò Paola Papaldo

Regina Elena National Cancer Institute Via Elio Chianesi, 53 - 00144 Rome, Italy

CONGRESS VENUE

The Scientific Sessions will be held on October 13th and 14th, 2011 at the Regina Elena National Cancer Institute - "Raffaele Bastianelli" Congress Centre (via Fermo Ognibene, 23 - 00144 Rome).

Language

The official language of the Congress is English. Simultaneous translation will not be provided

Certificate of attendance

Certificates will be issued to all registered participants who will expressly make request at the Secretariat Desk at the end of the Congress.

CME Credits

The Congress has received n. 2.2 CME Credits.

REGISTRATION INFORMATION

• Registration Fee

€ 360,00 (VAT 20% included)

• Reduced Registration Fee is available for doctors of the Regina Elena National Cancer Institue* € 100.00 (VAT 20% included)

* It is mandatory to send a valid statement of the Institute by email: breastcancer2011@aimgroup.eu (Obj. IRE STATEMENT)

The registration fee entitles delegates to the following:

- entry to scientific sessions
- 1 coffee break and 1 buffet lunch on October 13th and October 14th
- CME credits
- congress material
- certificate of attendance

Please enter the website www.aimgroupinternational.com/2011/breastcancer to register to the Congress through the on-line registration system